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Abstract
Background: WNT/β-catenin signaling plays an important role in the pathogenesis of idiopathic pulmonary fibrosis
(IPF); however, the role of WNT10A via transforming growth factor (TGF)-β signaling remains unclear.
Methods: We evaluated the expression of WNT10A and TGF-β in bleomycin (BLM)-treated mice and the
interactions between TGF-β or BLM and WNT10A in vitro. Additionally, we investigated IPF patients who underwent
video-assisted thoracoscopic surgery to determine whether the WNT10A expression is related to the survival.
Results: Increased WNT10A and TGF-β expressions were noted in the BLM-treated mice. Real-time PCR and
luciferase reporter assays demonstrated the levels of WNT10A and collagen in the fibroblasts cells to increase after
TGF-β administration. Conversely, WNT10A siRNA treatment inhibited the synthesis of collagen in the transfected
fibroblasts cells. A Kaplan-Meier survival analysis demonstrated a tendency toward a poor survival among the IPF
patients with a WNT10A-positive expression compared to those with a negative expression (Hazard ratio 5.351,
95 % CI 1.703-16.82; p = 0.0041). An overexpression of WNT10A was found to be significantly predictive of an acute
exacerbation of IPF (AE-IPF) (Odds ratio 13.69, 95 % CI 1.728-108.5; p = 0.013).
Conclusions: WNT10A plays an important role in the pathogenesis of IPF via TGF-β activation and it may also be a
sensitive predictor for the onset of an AE-IPF.
Keywords: Acute exacerbation, Idiopathic pulmonary fibrosis, Autopsy, Diffuse alveolar damage, WNT/β-catenin
pathway, Fibroblast
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive and
usually fatal lung disease of unknown etiology for which
no effective treatment currently exists [1, 2]. This
progressive disease has a high mortality rate, and current
models for predicting mortality have limited value in
identifying which patients will progress. The concept of
acute exacerbation of idiopathic pulmonary fibrosis
(AE-IPF) has been previously recognized [3], and the
findings for several cohorts suggest that this condition
is a major cause of death in patients with IPF [4, 5].
However, the molecular mechanisms and biomarkers for
predicting AE-IPF are currently only partially understood.
The histopathological features of patients with IPF
include the presence of fibroblastic foci of fibroblasts and
myofibroblasts consisting of aggregates of activated fibro-
blasts that produce excessive levels of extracellular matrix
components within the alveolar space at sites of epithelial
cell loss. Lung tissues derived from patients with IPF show
an increased activation response to fibrogenic cytokines,
such as transforming growth factor (TGF)-β1 [6]. The
epithelial-mesenchymal transition (EMT) of alveolar
epithelial cells is widely observed in patients with IPF.
Furthermore, TGF-β is a major inducer of the EMT and a
key mediator of fibrosis in the lungs.
WNTs constitute a family of secreted glycoproteins
that consist of at least 19 ligands in mammals and
mediate autocrine and paracrine effects by binding to
frizzled receptors and LDL-related protein 5/6 co-
receptors. Different WNT ligands signal through the
canonical β-catenin-dependent pathway or non-canonical
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β-catenin-independent pathway. Although WNT signaling
pathways have been shown to function in the setting of
pulmonary fibrosis [7–10], the relationship with WNT10A
is not well defined. We previously reported that WNT10A
is expressed in dermal and kidney fibroblasts [11, 12].
Moreover, WNT10A overexpression increases the ex-
pression of fibronectin at sites of these lesions. Further-
more, recent studies have shown that the interactions
between TGF-β and WNT are crucial for many bio-
logical processes [13]. Therefore, we hypothesized that
the WNT10A expression, which is required for TGF-β,
plays an important role in tissue repair and fibrotic
processes associated with IPF.
In this study, we evaluated the expression of WNT10A
in the setting of bleomycin (BLM)-induced lung fibrosis
in mice and assessed the interactions between TGF-β,
BLM and WNT10A at sites of fibroblast cells in vitro. In
addition, we investigated the prognosis and clinical im-
plications of WNT10A overexpression.
Methods
Animals
Experiments were performed in seven- or eight-week-
old male C57BL/6 J mice (wild-type mice) (Kyudo, Co.,
Ltd., Tosu, Japan) weighing 21–25 g. The mice were
maintained on a regular diet (CE-2, CLEA Japan, Inc.,
Tokyo, Japan). This study was reviewed and approved by
the Ethics Committee of Animal Care and Experimenta-
tion, University of Occupational and Environmental
Health, Japan, and were performed in accordance with
the National Institutes of Health guidelines. The mice
were divided into two groups (a bleomycin (BLM) group
and control group, n = 10/group). The mice received
intraperitoneal pentobarbital sodium and were intratra-
cheally administered 2.0 mg/kg of BLM (Nippon,
Kayaku, Tokyo, Japan) dissolved in 50 μl sterile saline or
50 μl sterile saline alone as a control. The body weights
were measured daily beginning on the day when BLM or
sterile saline was administered.
Bronchoalveolar lavage (BAL) and sample collection
On day 14, the mice were anesthetized by an injection of
pentobarbital sodium. Immediately thereafter, a midline
neck incision was made, and the trachea was cannulated.
The left lung was lavaged using 2.4 mL cooled sterile
saline, 0.8 mL each time, for a total of three times. The
brochoalveolar lavage fluid (BALF) obtained from these
three washes were collected together. After counting the
cell numbers in the BALF, the cells were cytospun and
stained with Diff-Quick for cell classification according
to the manufacturer’s protocol.
The right lung was harvested with RNAlater RNA
Stabilization Reagent (QIAGEN, Germantown, MD, USA)
and frozen at -70 °C for Real-Time quantitative polymerase
chain reaction (qPCR). The remaining left lungs were
fixed in 15 % formalin neutral buffer solution (Wako,
Osaka, Japan) and embedded in paraffin before a
histological analysis.
Real-Time qPCR
One μg of total RNA was reverse-transcribed according to
the manufacturer’s protocol. Quantification of the expres-
sion levels of TGF-β1, monocyte chemotactic protein
(MCP)-1, collagen, type I, alpha 1 (COL1A1), WNT3A,
WNT5A, WNT7B, WNT10A, WNT10B and glyceral
dehyde-3-phosphate dehydrogenase (GAPDH) mRNA was
performed by real-time qPCR on an ABI prism 7000
sequence detection system (Applied Biosystems, Foster
City, CA). The following TaqMan Gene Expression primers
were used: TGF-β1 (Mm01178820_m1), MCP-1 (Mm004
46214_m1), COL1A1 (Mm00801666_g1 and Hs001640
04_m1), WNT3A (Hs00263977_m1), WNT5A (Hs009985
37_m1), WNT7B (Hs00536497_m1), WNT10A (Mm0043
7325_m1 and Hs00228741_m1), WNT10B (Hs005596
64_m1) and GAPDH (Mm99999915_g1 and Hs02758
991_g1).
Histopathological evaluation of tissue sections
Tissue sections (4-μm thick) were cut and stained with
hematoxylin and eosin (H&E), an anti-α-SMA antibody
and Masson’s trichrome using standard procedures. We
evaluated the effects of BLM-induced pulmonary fibrosis
by means of the Ashcroft score [14]. In addition, to inves-
tigate the expression of WNT10A from the morphological
perspective in BLM-induced pulmonary fibrosis, an im-
munohistochemical analysis was performed.
Cell culture and treatment
The normal human lung fibroblast cell line, IMR-90
(Japanese Collection of Research Bioresources, Osaka,
Japan), and the IPF lung fibroblast cell line, LL97A
(American Type Culture Collection, Manassas, VA,
USA), were cultured in Eagle’s Minimum Essential
Medium (MEM) with Earle’s salt (GIBCO) supplemented
with 10 % fetal bovine serum, 100 U/ml of penicillin,
100 μg/ml of streptomycin and 0.1 mM nonessential amino
acids. The African green monkey fibroblast line, COS1
(American Type Culture Collection, Manassas, VA, USA),
was also cultured as described previously [12]. IMR-90 and
LL97A cells were plated in six-well plates and stimulated
for 24 h with recombinant TGF-β1 (5 ng/ml) (R&D
Systems, Inc., Minneapolis, USA). We performed a Real-
Time qPCR analysis to examine the time dependency of
the expression profiles of the WNT ligands and COL1A1
by stimulation with TGF-β1, and performed the Sircol
collagen assay to quantify the total collagens. In addition,
whole-cell lysates were prepared and subjected to Western
blot analyses.







Fig. 1 Inflammation in BLM-treated mice a The body weight changes of BLM-treated mice and control mice over time (n = 10 each). *p < 0.05. b The
results of an analysis of the total cell numbers and cell types in the bronchoalveolar lavage fluid (BALF) (n = 10 each). *p < 0.05. c The expression levels
of MCP-1, TGF-β and COL1A1 mRNA were increased in the lungs from the BLM-treated mice compared to the control mice (n = 6 each). *p < 0.05. d
The Ashcroft score in the BLM-treated mice was significantly increased compared to that of the control mice (n = 4 each). *p < 0.05. e Representative
photomicrographs of lung tissue sections stained with H&E, Masson’s trichrome or with an anti-α-SMA antibody. All results are expressed as
the means ± SEM
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Antibodies
For the Western blotting analyses and immunohisto-
chemical studies, the following antibodies were used:
anti-WNT10A (SAB3500393) and anti-β-actin (A5316)
were purchased from Sigma-Aldrich (MO, USA), anti-α-
SMA (M851) was purchased from Dako (Tokyo, Japan),
and anti-β-catenin (9562) was purchased from Cell
Signaling Technology (MA, USA).
Plasmid construction and transfectants
To prepare the human WNT10A-luciferase reporter
plasmid, the pGL3 human WNT10A promoter-luciferase
plasmid [12], pEBMulti-vector (Wako, Osaka, Japan) and
pMACS Kk.II (Miltenyi Biotec, Bergisch Gladbach,
Germany) were modified. This plasmid was transfected
into COS1 cells. In the COS1 cells, EBNA1, H-2Kk,
EmGFP and hygromycin were all expressed. The
EBNA1 and OriP sequences could replicate this plas-
mid in COS1 cells. After 72 h, transfected cells were
separated using an anti-H-2Kk antibody conjugated to
magnetic beads based on the manufacturer’s instruction
manual, and were cultured in medium containing
400 ng/ml hygromycin for two weeks. The transfection
efficiency was estimated based on the EmGFP expres-
sion in living cells.
Reporter assay
The reporter assay was described previously [12]. In
brief, 4x104 human WNT10A-luc transfectants in 12
well plates were cultured for 12 h, then were treated
with BLM (0 to 50 uM) or 5 ng/ml TGF-β1 for 24 h.
For the recovery assay, 4x104 human WNT10A-luc
transfectants were treated with 50 uM BLM for the
indicated time, and were cultured with new medium
A B
C D
Fig. 2 TGF-β1 induces WNT10A expression in fibroblasts. a The results of an analysis of Hoechst (blue), WNT10A (red) and Phalloidin (green)
staining in LL97A cells as indicated by immunofluorescence. The WNT10A expression after the administration of TGF-β1 (5 ng/ml) in LL97A cells
was analyzed using a Western blot analysis. b LL97A and IMR-90 cells were treated with TGF-β1 (5 ng/ml), and at the indicated time points, the
mRNA level of WNT10A was assessed by real-time qPCR compared to the untreated cells, and the results are expressed as the means ± SEM.
*p < 0.05. c The WNT family genes (WNT3A, WNT5A, WNT7B, WNT10A, WNT10B and β-catenin) were analyzed by real-time qPCR compared to
the untreated cells, and the results are expressed as the means ± SEM. *p < 0.05. d The luciferase activity of the WNT10A promoter was
measured 24 h after TGF-β1 (5 ng/ml) stimulation, and the results are expressed as the means ± SEM. *p < 0.05
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without BLM for 48 h. The results shown were normal-
ized to the protein concentrations measured using the
Bradford method and are representative of at least three
independent experiments.
Western blot analysis
Cells were lysed using RIPA buffer containing 50 mM
Tris, 150 mM NaCl, 1.0 % NP-40, 0.5 % sodium deoxy-
cholate, 1.0 mM EDTA, 0.1 % SDS and 0.01 % sodium
azide at a pH of 7.4 (Rockland, Gilbertsville, PA, USA),
plus a mix of protease inhibitors (Nakalai tesque, Kyoto,
Japan). The protein concentration was analyzed using a
protein assay kit, with bovine serum albumin used as the
standard (Thermo Fisher Scientific, Rockford, IL, USA).
A 30 μg aliquot of total protein was typically used for
the Western blot analyses. The 30 μg of protein from
whole-cell lysates were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and trans-
ferred to polyvinylidene difluoride membranes (Bio-Rad,
USA). The blotted membranes were treated with 5 %
(w/v) skimmed milk in 10 mM Tris, 150 mM NaCl and
0.2 % (v/v) Tween 20, and were incubated for 1 h at
room temperature with the primary antibody. An anti-β-
actin antibody was used as an internal control at a
1:1,000 dilution. The membranes were then incubated
for 45 min at room temperature with a peroxidase-
conjugated secondary antibody, and were visualized
using an ECL kit (GE Healthcare Bio-Science, Bucking-
hamshire, UK). The chemiluminescence was detected
with the Light-Capture AE-6972 (ATTO, Tokyo, Japan).
Western blots were scanned densitometrically using the
Image J software program.
Small interfering RNA transfection
Specific knockdown was achieved using small interfering
RNA against WNT10A (sc-76927) or a control siRNA
(sc-37007) (all from Santa Cruz Biotechnology, Inc.).
IMR-90 and LL 97A cells were transfected with WNT10A
siRNA for 72 h according to the manufacturer’s protocol.
Cells were harvested for 24 and 48 h (for mRNA and
protein determination, respectively.)
Sircol collagen assay
IMR-90 or LL97A cells were plated at a density of 10,000
cells/well in six-well plates, synchronized for 24 h in
serum-free medium, and treated for 24 h as indicated.
The total collagen content was determined using a Sircol
Collagen Assay Kit (Biocolor Ltd., Carrickfergus, Northern
Ireland, U.K.) according to the manufacturer’s instruc-
tions. Briefly, equal volumes of conditioned medium
were incubated with Isolation and Concentration Re-
agent at 4 °C overnight. Samples were then centrifuged
at 12,000 rpm for 10 min using a microcentrifuge, and
Sircol Dye Reagent was then added to the pellet and
incubated with shaking for 30 min. Samples were
centrifuged as above to allow for packing of the
collagen-dye complex. The supernatant was discarded,
and cold Acid-Salt Wash Reagent was added without
disrupting the pellet. Samples were centrifuged as
above, the supernatant was discarded and Alkali Re-
agent was added to the pellet. Samples were vortexed
and then the absorbance was measured at 595 nm using
a spectrophotometer. The total collagen concentration
was estimated using a collagen standard.
Immunofluorescence staining
IMR-90 cells were plated onto chamber slides for 72 h
and fixed with 15 % formalin for 10 min after washing
with PBS. The cells were incubated with 0.2 % (v/v)
Triton X-100 with PBS for 10 min at room temperature.
The cells were then treated with 4 % (w/v) skimmed
milk (DS Pharma Biomedical Co., Ltd., Osaka, Japan) in
PBS and incubated for 30 min at room temperature,
washed with PBS and incubated for 1 h at room
temperature with an anti-WNT10A antibody and subse-
quently with an Alexa Fluor 546-conjugated secondary
antibody (red) (Invitrogen, Carlsbad, CA, USA) for an
additional 30 min. For actin filament staining, phalloidin
Alexa Fluor 488 (green) (Lonza, Walkersville, USA) was
used, and for nuclear staining, Hoechst 33258 (blue)
(Dojindo, Kumamoto, Japan), was used.
Preparation of human lung samples
Thirty patients with IPF diagnosed according to the cri-
teria of the 2011 IPF guidelines [15] who consecutively
Fig. 3 Maps of the plasmid vectors used for the mammalian
luciferase reporter assays
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underwent video-assisted thoracoscopic surgery (VATS)
lung biopsies at our university hospital from January 1,
2006 to December 31, 2012 were retrospectively ana-
lyzed. All cases were originally diagnosed histologically
as diagnostic of usual interstitial pneumonia (UIP) by
two pulmonary pathologists. This study was approved by
the University of Occupational and Environmental
Health, Japan Institutional Review Board (H26-004). We
retrospectively studied the various data of the patients
with IPF, including their history of AE-IPF. AE-IPF was
defined according to a previous report [3].
Immunohistochemistry of human lung tissue samples
Immunohistochemical staining was performed according to
the antibody-linked dextran polymer method for antibody-
bridge labeling, with hematoxylin counterstaining
(EnVision; DAKO Cytomation Co., Glostrup, Denmark).
Deparaffinized and rehydrated 4-μm sections were incu-
bated in 10 % H2O2 for five minutes to block the endog-
enous peroxidase activity. The sections were subsequently
rinsed and incubated with rabbit polyclonal anti-
WNT10A (diluted 1:100) antibodies for 30 min. The
second antibody-peroxidase-linked polymers were then
applied, and the sections were incubated with a solu-
tion consisting of 20 mg of 3.3′-diaminobenzidine
tetrahydrochloride, 65 mg of sodium azide and 20 ml of
30 % H2O2 in 100 ml of Tris-HCL (50 mM, pH7.6).
After counterstaining with Meyer’s hematoxylin, the
sections were observed under a light microscope. The
sections were first scanned at low-power for all fields
A B
C D
Fig. 4 BLM induces WNT10A and β-catenin expressions. a The mRNA level of WNT10A and β-catenin in BLM-treated and control mice was
assessed by real-time qPCR (n = 10 each). *p < 0.05. b Lung tissue specimens of BLM-treated and control mice were stained with anti-WNT10A
and β-catenin antibodies. The arrow indicates the WNT10A and β-catenin expressions in fibroblasts. c COS1 cells stably transfected with
WNT10A-luciferase reporter plasmid which can replicate in the cells were treated with the indicated concentration of BLM. After 24 h, a luciferase
assay was performed and the results are expressed as the means ± SEM. *p < 0.05. d The transfectants described in (c) were treated with 50 uM
BLM for the indicated times, and then were changed to a new medium. After 48 h, a luciferase assay was performed as a recovery assay, and the
results are expressed as the means ± SEM. *p < 0.05
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(original magnification: × 40) with UIP and non-UIP,
respectively, to account for the heterogeneity of the
distribution. The sections stained with WNT10A were
then counted at high-power (original: × 400) magnifica-
tion. The number of fibroblastic stromal cells within
fibroblastic foci showing positive cytoplasmic staining
and the pattern of staining were recorded. Necrotic
tissues and lymphoid cells were not included in the
recording. Immunoreactivity for WNT10A in each case
was assessed semi-quantitatively by evaluating the
proportion of positive fibroblastic cells relative to the
total number of fibroblastic stromal cells in 5 % incre-
ments (0 %, 5 %, 10 %…). We selected and validated
immunohistochemical cut-off scores for WNT10A
positivity (10 %) based on the performance of a receiver
operating characteristic (ROC) curve analysis. Accord-
ing to the ROC curve, the patients were divided into
two groups, as follows: positive for more than 10 %
positivity and negative for less than 9 % positivity.
All histological and immunohistochemical slides were
evaluated by two independent observers (certified surgi-
cal pathologists at the Department of Pathology) using a
blind protocol design (the observers were blinded to the
clinicopathological data). The degree of agreement
between observers was excellent (>0.9) for all antibodies
investigated, as measured by the interclass correlation
coefficient. In the few instances of disagreement, a
consensus score was determined by a third board-
certified pathologist in our department.
Statistical analysis
The data are presented as the mean ± SEM. Differences
between two groups were analyzed for statistical signifi-
cance using Student’s t-test. The probability of overall
A B
C D
Fig. 5 The WNT10A expression regulated collagen production. a Cells were treated with TGF-β1 (5 ng/ml), and at the indicated time points, the
mRNA level of COL1A1 was assessed by real-time qPCR. *p < 0.05. b Collagen production was measured 24 h after TGF-β1 (5 ng/ml) stimulation.
*p < 0.05. c The efficacy of WNT10A silencing was evaluated by immunoblotting for β-catenin and WNT10A proteins in IMR-90 and LL97A cells.
*p < 0.05. d LL97A and IMR-90 cells transfected with indicated siRNAs for 72 h were treated with TGF-β1 (5 ng/ml). After 24 h, the mRNA level of
COL1A1 was assessed by real-time qPCR. *p < 0.05. All results are expressed as the means ± SEM
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survival was estimated using the Kaplan-Meier method
and compared using the log-rank test. Correlation coeffi-
cients were calculated using Spearman’s rank correlation
coefficient. The associations between acute exacerbation
within one year on VATS and the explanatory variables
were examined using a multiple logistic regression ana-
lysis adjusted for the effects of confounding variables. In
the logistic regression, we selected the set of variables to
be included in the model according to the backward
elimination method. All statistical analyses were per-
formed using the Statistical Package for Social Sciences
(SPSS, version 19). Statistical values of p < 0.05 were
considered to be significant.
Results
Analysis of pulmonary inflammation and fibrosis in
BLM-treated mice
We first evaluated the pulmonary inflammation and
fibrosis in the BLM-treated mice. The BLM-treated mice
lost more weight than the saline-treated mice (control
mice) (Fig. 1a). After 14 days, the number of inflamma-
tory cells in the BAL fluid (BALF) was increased in the
BLM-treated mice (Fig. 1b). A real-time qPCR analysis
showed more abundant MCP-1, TGF-β1 and COL1A1
mRNA in the homogenates of lungs from BLM-treated
mice compared to those of the control mice (Fig. 1c).
Serial lung sections from mice obtained after BLM treat-
ment for 14 days were stained with H&E, and α-SMA
antibody and Masson’s trichrome stain. The Ashcroft
score in the BLM-treated mice was significantly increased
compared to that in the control mice (Fig. 1d). Represen-
tative histological sections from the lungs of mice in each
experimental group are shown in Fig. 1e.
TGF-β1 induces WNT10A expression in fibroblast cells
To confirm whether TGF-β1 induces WNT10A expres-
sion, we used LL97A cells, which were derived from
human lung fibroblast cells from IPF patients. As shown
in Fig. 2a, the LL97A cells spontaneously expressed
WNT10A. In addition, we found that WNT10A expres-
sion was activated by TGF-β1 using a Western blot
analysis. A real-time qPCR analysis showed that TGF-β1
treatment increased the WNT10A mRNA expression in
LL97A cells, as well as in a human diploid fibroblast
strain, IMR-90 cells (Fig. 2b). The maximal expression of
the mRNA was observed at three hours after treatment.
Next, we compared the mRNA expression level of
WNT10A and other members of the WNT family,
WNT3A, 5A, 7B and 10B, using IMR-90 and LL97A
cells. The expression of WNT10A mRNA was induced
most strongly by TGF-β1 treatment among these various
genes (Fig. 2c). To confirm whether the mRNA expres-
sion was increased by effects of transcriptional regula-
tion, we transfected a reporter plasmid containing the
WNT10A promoter (Fig. 3) into COS1 cells (fibro-
blasts from an African green monkey), and a lucifer-
ase assay was performed. The WNT10A luciferase
activity was increased in the fibroblasts by TGF-β1
administration (Fig. 2d).
BLM induces WNT10A expression in fibroblasts
To confirm whether BLM induces WNT10A, we investi-
gated the lungs from BLM-treated mice using real-time
qPCR and immunohistochemical analyses. Both the
mRNA expression and protein staining of WNT10A in
the lungs of BLM-treated mice were increased compared
with those in control mice (Fig. 4a and b). To confirm
whether this induction was also observed in vitro, COS1
cells transfected with a WNT10A reporter plasmid were
used. Unfortunately, the COS1 cells died after sustained
treatment with BLM, and the luciferase activity was not
increased (Fig. 4c). However, if highly-concentrated
(up to 50 uM) BLM was used, short-term treatment
induced WNT10A promoter activity (Fig. 4d).
WNT10A expression induces collagen production
To elucidate the mechanisms underlying the role of
WNT10A in pulmonary fibrosis, we focused on collagen,
one of the components of the extracellular matrix. As
shown in Fig. 5a, the COL1A1 mRNA expression levels
of IMR-90 and LL97A cells were increased by TGF-β1
treatment in a time-dependent manner. We also investi-
gated the quantity of total collagens in fibroblasts treated
with TGF-β1. The total collagen level was significantly
increased by treatment with TGF-β1 in both cell line
(Fig. 5b). To confirm whether WNT10A was associated
Table 1 Comparison between the two groups of IPF patients:






Sex, male, No 11 14 0.782
Age, year, mean 70 71.2 0.711
Brinkman Index, mean 856.9 943.8 0.773
BMI, kg/m2, mean 24.9 22.3 0.103
PaO2, Torr, mean 80.5 85.2 0.363
SpO2, %, mean 97.6 96.9 0.263
FVC, L, mean 2.79 2.88 0.651
% FVC, %, mean 87.3 86.7 0.934
FEV1.0 %, %, mean 73.3 75.3 0.967
% DLCO, %, mean 63.3 65.2 0.662
KL-6, U/ml, mean 1016.6 747.2 0.563
SP-D, ng/ml, mean 168.4 157.7 0.779
LDH, IU/L, mean 235.7 222.5 0.934
MMRC, mean 1.15 1.35 0.509
Data are presented as the n and means
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with the collagen expression, we employed a RNAi tech-
nique (using siRNA). As shown in Fig. 5c, WNT10A
expression was strongly decreased by treatment with a
siRNA against WNT10A in both fibroblast cell lines.
Consistent with a previous report [16], β-catenin expres-
sion was reduced with the decrease in WNT10A. The
expression of COL1A1 mRNA in both fibroblast cell lines
was decreased by treatment with WNT10A siRNA, even
if the cells had been activated by TGF-β1 (Fig. 5d).
Patient characteristics
To investigate the clinical implications of WNT10A
overexpression, we obtained lung tissue samples
from 30 IPF patients with a histological UIP pattern
who underwent a VATS lung biopsy. There were 25
males and five females with a mean age of 70.7 years
old. These patients with IPF were divided into two
groups (a WNT10A-positive group [n = 13] and a
WNT10A-negative group [n = 17]) as stated previously.
No significant differences were observed in clinical vari-
ables between the groups (Table 1). Among the 30
patients with IPF, 10 (33.3 %) patients experienced an
AE-IPF, including nine patients (90 %) with AE-IPF
within a year from VATS. Fifteen patients (50.0 %)
died during the observation period, including six
(40.0 %) due to acute exacerbation, four (26.7 %) due
to respiratory failure, four (26.7 %) due to cancer and
one (6.7 %) due to other known causes. The median




Fig. 6 The clinicopathological significance of WNT10A expression in patients with IPF. a An immunohistochemical analysis of the WNT10A
protein expression in the healthy control and patients with IPF. The left panels show normal human lung tissue treated for the localization of
WNT10A using immunohistochemistry reactivity in the smooth muscle of vessels (single arrows) and airways (double arrows). The right upper
panels show a WNT10A-positive case, which demonstrated a specific expression of WNT10A in one part of the spindled cells (fibroblasts, indicated
by arrows in a high-power view of the right panel) at a site of pulmonary fibroblastic foci (boxes, low-power view of left panel). The right bottom
panels indicate a WNT10A-negative case in patients with IPF. b The results of the Kaplan-Meier survival analysis of the overall survival in IPF
patients who were WNT10A-positive or negative
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Survival analysis using the Kaplan-Meier method
To confirm whether WNT10A is an effective prognostic
factor for patients with IPF, we stained human lung tissue
samples with anti-WNT10A antibody. As shown in Fig. 6a,
WNT10A protein was observed to be focally expressed in
pulmonary fibroblastic foci. A significant difference was
noted between the positive and negative groups in terms of
the survival time (log-rank, hazard ratio [HR] 5.351, 95%CI
1.703-16.82; p = 0.0041) (Fig. 6b). Among the patients with
positive WNT10A staining, eight patients (61.5 %) experi-
enced an AE-IPF within a year from the VATS.
Role of WNT10A as a prognostic factor for acute
exacerbation of IPF
To investigate the risk factors for an acute exacerbation of
IPF, we analyzed the clinical variables (sex, age, %FVC, KL-
6, SP-D, LDH, modified Medical Research Council
[MMRC] score, HRCT fibrosis score [17] and WNT10A)
using a multiple logistic regression analysis. The cor-
relations between the baseline WNT10A expression and
clinical variables are shown in Figs. 7 and 8, and were deter-
mined using Spearman’s rank correlation coefficient. There
was no correlation between the expression of WNT10A
Fig. 7 The results of the correlation analysis between WNT10A and the clinical variables in patients with IPF. The Spearman correlation
coefficients between these variables were determined as shown on the plots
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and other clinical variables. The results of the multiple
logistic regression analysis are shown in Table 2. The over-
expression of WNT10A was identified as the only variable
significantly predictive of acute exacerbation (Odds ratio
[OR] 13.69, 95 % CI 1.728-108.5; p = 0.013).
Discussion
IPF is a chronic, progressive and fibrosing disease char-
acterized by the proliferation of fibroblasts with depos-
ition of type I collagen within the alveolar wall, which
results in scarred non-functional airspaces, hypoxia and
death due to respiratory failure [18]. We herein report
that TGF-β1-induced WNT10A expression leads to the
production of collagen in fibroblasts. By performing in
vitro and in vivo experiments, we provided evidence that
these mediators are induced at the mRNA level, as well
as at the protein level. In addition, WNT10A is a sensi-
tive predictor for the onset of AE-IPF, and its expression
is associated with an increased risk of mortality in pa-
tients with IPF. To the best of our knowledge, our data
provide the first evidence of a link between WNT10A
and the development of a fibrosis response in IPF.
Fig. 8 The correlation between WNT10A and the clinical variables in patients with IPF in the WNT10A-positive group. No significant correlations
were noted between these clinical variables and positivity of WNT10A based on the Spearman’s correlation coefficients
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Therefore, WNT10A may represent a novel pathway con-
tributing to the persisting phenotype of lung fibrosis.
TGF-β is a major inducer of EMT and a key mediator
of fibrosis in the lung, and it also activates a large
number of intracellular signaling cascades [19]. TGF-β
signaling predominantly occurs through the Smad-
dependent pathways; however, there is evidence showing
that TGF-β induces the activation of non Smad-dependent
signaling in EMT [20], particularly regarding the interac-
tions between TGF-β and the β-catenin pathway [21]. In
addition, TGF-β signaling can lead to β-catenin signaling
through a WNT-dependent pathway. Recent evidence has
suggested that WNT signaling, especially the canonical
WNT/β-catenin pathway, may be involved in the onset of
TGF-β-mediated fibrosis [13].
WNT10A has multiple functions in regulating cell prop-
erties, such as proliferation [22, 23], and we also previ-
ously reported that WNT10A overexpression is strongly
related to fibrosis in the organs outside the lung [11, 12].
Although prior studies have suggested that several WNT
ligands play a central role in epithelial and mesenchymal
proliferation and collagen production and enhanced gene
expression in patients with IPF [8, 10, 24, 25], no previous
studies have so far reported the clinical implications of
WNT10A expression in patients with IPF. Several reports
have found that the upregulation of TGF-β signaling
induces an increase in WNT3A [26], WNT5A [27, 28],
and WNT7B [29]. In the present study, overexpression of
WNT10A was largely related to an upregulation of
collagen production via TGF-β signaling (Fig. 9). As a
result, smad binding elements (SBEs), containing the
5′-AGAC-3′ element [30], are important for under-
standing the relationship between WNT10A and TGF-β.
In fact, the 5′-AGAC-3′ SBE was observed at two differ-
ent spots within 200 bp from the transcriptional start
point of the WNT10A gene the present study (data not
shown). We believe that these findings indicate a close
relationship between WNT10A expression and the upreg-
ulation of TGF-β signaling.
β-Catenin is a key component for the alveolar epithe-
lium in lung development [31], where it exists as a
component of the adherens junction, and it is bound to
E-cadherin, and also is found in the cytoplasm where it
induces signaling functions [32]. The role of β-catenin in
the lung is less clear, but some studies have demon-
strated that a relationship may exist between the expres-
sion of β-catenin and pulmonary fibrosis. Kim and
colleagues demonstrated that the intratracheal admi-
nistration of siRNA targeting β-catenin also caused a
decrease in lung fibrosis after BLM [33]. In response to
TGF-β1, β-catenin is liberated from the E-cadherin
adherens junctions and thereafter translocates to the
nucleus where it mediates the activation of the transcrip-
tion factors promoting collagen transcription [34]. In
contrast, Tanjore and colleagues demonstrated that β-
catenin in the alveolar epithelium protects against BLM-
induced fibrosis [35]. In the present study, we focused on
the expression of WNT10A in fibroblasts, and showed
that WNT10A activated by TGF-β1 is associated with the
production of collagen, therefore, further investigation is
necessary to clearly elucidate the role of β-catenin.
The extracellular matrix, such as collagen plays a
central role in the onset of lung fibrosis [36]. We found
WNT10A to be expressed in regions containing fib-
roblasts and WNT10A is therefore implicated in the
production of collagen. In addition, we showed that
markedly increased levels of COL1A1, which indicates
the presence of collagen synthesis, were observed to
decrease thereby reducing the activity of WNT10A in
vitro. IPF is characterized by the unrelenting progression
of fibrotic tissue formation, with the expansion of fibro-
blasts within the alveolar walls and the deposition of type
Fig. 9 The role of WNT10A in lung fibrosis. A proposal model
depicting the role of WNT10A in lung fibrosis is shown. Injury
leads to increased WNT10A expression, either directly or via
TGF-β1 signaling, in fibroblasts. Aberrant activation of WNT10A is
involved in mediating the fibrogenesis in patients with IPF by
inducing the accumulation of collagen and fibronectin
Table 2 Logistic regression analysis for the factors predicting
AE-IPF
Variables p-value OR (95 % CI)
WNT10A 0.013 13.69 (1.728 to 108.5)
LDH 0.088 1.022 (0.997 to 1.047)
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I collagen, thus resulting in the obliteration of airspaces and
the subsequent impairment of gas exchange that in turn
leads to progressive hypoxia [15, 37, 38]. Therefore, our
data indicate that inhibiting WNT10A might be an effective
approach to target fibrosis in patients with IPF.
The molecular mechanisms underlying AE-IPF are
poorly understood and little is known about the sensitive
biomarkers for predicting acute exacerbation. Previous
studies have reported several genetic factors associated
with mortality in IPF, such as erythrocyte complement
receptor 1 [39], telomerase reverse transcriptase [40]
and the MUC 5B gene [41]. In addition, previous studies
also have reported several biomarkers to be significantly
higher in AE-IPF than in stable IPF [42–44]. However,
none of these markers were found to be associated with
the risk of AE-IPF. One previous report suggested that
the baseline serum KL-6 level, a complex sialo-
carbohydrate glycoprotein present in the human MUC1
mucin, may be a sensitive predictor for the onset of AE-
IPF [45]. In our study, the baseline KL-6 level was not
found to correlate with AE-IPF; however, patients with a
WNT10A overexpression did have a significantly poor
prognosis and the WNT10A expression was thus identi-
fied to be a sensitive predictor for AE-IPF. The mole-
cular mechanisms underlying AE-IPF remain poorly
understood, although Collard and colleagues suggested
that stretch-dependent TGF-β activation may promote
the development of AE-IPF during VATS [3]. Our
findings suggest that WNT10A overexpression via the
TGF-β signal leads to an acceleration of fibroprolifera-
tion, such as that observed in AE-IPF. In fact, WNT10A
overexpression was found to be the only risk factor for
AE-IPF according to the findings of a multivariate
analysis in the present study.
Conclusions
Our results show that the WNT10A expression therefore
plays an important role in pulmonary fibrosis via TGF-β1
signaling. As a result, inhibiting WNT10A might be a
novel approach to treat patients with IPF. In addition, the
WNT10A expression may also be a sensitive predictor for
the onset of AE-IPF.
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